Shasun Acquires Global Rights for Ibuprofen from Scolorpharma - The New Indian Express

Shasun Acquires Global Rights for Ibuprofen from Scolorpharma

Published: 05th May 2014 03:16 PM

Last Updated: 05th May 2014 03:16 PM

Shasun Pharmaceuticals today acquired the global rights to develop and commercialise the 12-hour extended release analgesic tablets Ibuprofen from US-based ScolorPharma along with those of pain killer Nuprin trademark for an undisclosed sum.

The acquisition also includes the controlled release technology of Ibuprofen 12-hour extended release OTC, the company said in a statement.

"The acquisition complements Shasun's strategy to expand its range of non-steroidal anti-inflammatory drug (NSAIDS) products through novel, safe and efficacious technologies, including applications across its Ibuprofen franchise," it said.

Commenting on the move, Shasun Pharmaceuticals Managing Director S Abhaya Kumar said: "The acquisition is the first among a series of strategic initiatives in our quest to continue to enhance our global leadership in the NSAIDS category."

Shashun is among top vertically integrated manufacturers of Ibuprofen and its derivatives, from actives to formulated packaged products for both prescription and over-the-counter markets.

Shares of Shashun Pharmaceuticals were trading at Rs 129.45 per scrip in the afternoon trade, up 1.33 per cent from the previous close on the BSE.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

Read More

follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook